Heron Therapeutics Inc (HRTX) financials
Heron Therapeutics revenue and earnings by year
Heron Therapeutics's revenue was $155 million in the fiscal year to December 31, 2025, up 7.4% from the year before. Net income was -$20.2 million, -13.0% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 70.4% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155 | 144 | 127 | 108 | 86 | 89 | 146 | 77 | 31 | 1 |
| Revenue growth | 7.4% | 13.6% | 18.0% | 24.7% | -2.6% | -39.3% | 88.4% | 151.8% | 2305.6% | — |
| Gross profit | 114 | 106 | 62 | 53 | 40 | 52 | 84 | 50 | 26 | 1 |
| Gross margin | 73.3% | 73.2% | 48.8% | 49.0% | 46.7% | 59.2% | 57.8% | 64.5% | 85.1% | 97.3% |
| Operating income | -3 | -12 | -111 | -175 | -219 | -228 | -211 | -184 | -195 | -171 |
| Operating margin | -1.6% | -8.0% | -87.1% | -162.2% | -253.3% | -257.4% | -144.3% | -237.4% | -632.4% | -13363.2% |
| Net income | -20 | -14 | -111 | -182 | -221 | -227 | -205 | -179 | -197 | -173 |
| Net margin | -13.0% | -9.4% | -87.0% | -169.1% | -255.6% | -256.4% | -140.3% | -230.8% | -641.9% | -13537.4% |
| Diluted EPS | -$0.12 | -$0.09 | -$0.80 | -$1.67 | -$2.24 | -$2.50 | -$2.50 | -$2.47 | -$3.67 | -$4.55 |
| Free cash flow | -28 | -24 | -60 | -149 | -206 | -192 | -132 | -201 | -173 | -137 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open HRTX in Markets.
How Heron Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| CINVANTI | $21.8M | 57.9% |
| ZYNRELEF | $11.1M | 29.4% |
| Aponvie | $4.28M | 11.4% |
| SUSTOL | $540K | 1.4% |
See also: HRTX returns
No forecast, no recommendation. This page describes Heron Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.